{"pmid":32473352,"title":"Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.","text":["Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.","The 2019 novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak has caused a large number of deaths, with thousands of confirmed cases worldwide. The present study followed computational approaches to identify B- and T-cell epitopes for the spike (S) glycoprotein of SARS-CoV-2 by its interactions with the human leukocyte antigen alleles. We identified 24 peptide stretches on the SARS-CoV-2S protein that are well conserved among the reported strains. The S protein structure further validated the presence of predicted peptides on the surface, of which 20 are surface exposed and predicted to have reasonable epitope binding efficiency. The work could be useful for understanding the immunodominant regions in the surface protein of SARS-CoV-2 and could potentially help in designing some peptide-based diagnostics. Also, identified T-cell epitopes might be considered for incorporation in vaccine designs.","Infect Genet Evol","Vashi, Yoya","Jagrit, Vipin","Kumar, Sachin","32473352"],"abstract":["The 2019 novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak has caused a large number of deaths, with thousands of confirmed cases worldwide. The present study followed computational approaches to identify B- and T-cell epitopes for the spike (S) glycoprotein of SARS-CoV-2 by its interactions with the human leukocyte antigen alleles. We identified 24 peptide stretches on the SARS-CoV-2S protein that are well conserved among the reported strains. The S protein structure further validated the presence of predicted peptides on the surface, of which 20 are surface exposed and predicted to have reasonable epitope binding efficiency. The work could be useful for understanding the immunodominant regions in the surface protein of SARS-CoV-2 and could potentially help in designing some peptide-based diagnostics. Also, identified T-cell epitopes might be considered for incorporation in vaccine designs."],"journal":"Infect Genet Evol","authors":["Vashi, Yoya","Jagrit, Vipin","Kumar, Sachin"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473352","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.meegid.2020.104382","keywords":["diagnostics","epitopes","sars-cov-2","spike protein"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193388548096,"score":9.490897,"similar":[{"pmid":32022276,"pmcid":"PMC7166505","title":"Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV.","text":["Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV.","The 2019 novel coronavirus (2019-nCoV) outbreak has caused a large number of deaths with thousands of confirmed cases worldwide, especially in East Asia. This study took an immunoinformatics approach to identify significant cytotoxic T lymphocyte (CTL) and B cell epitopes in the 2019-nCoV surface glycoprotein. Also, interactions between identified CTL epitopes and their corresponding major histocompatibility complex (MHC) class I supertype representatives prevalent in China were studied by molecular dynamics simulations. We identified five CTL epitopes, three sequential B cell epitopes and five discontinuous B cell epitopes in the viral surface glycoprotein. Also, during simulations, the CTL epitopes were observed to be binding MHC class I peptide-binding grooves via multiple contacts, with continuous hydrogen bonds and salt bridge anchors, indicating their potential in generating immune responses. Some of these identified epitopes can be potential candidates for the development of 2019-nCoV vaccines.","J Med Virol","Baruah, Vargab","Bose, Sujoy","32022276"],"abstract":["The 2019 novel coronavirus (2019-nCoV) outbreak has caused a large number of deaths with thousands of confirmed cases worldwide, especially in East Asia. This study took an immunoinformatics approach to identify significant cytotoxic T lymphocyte (CTL) and B cell epitopes in the 2019-nCoV surface glycoprotein. Also, interactions between identified CTL epitopes and their corresponding major histocompatibility complex (MHC) class I supertype representatives prevalent in China were studied by molecular dynamics simulations. We identified five CTL epitopes, three sequential B cell epitopes and five discontinuous B cell epitopes in the viral surface glycoprotein. Also, during simulations, the CTL epitopes were observed to be binding MHC class I peptide-binding grooves via multiple contacts, with continuous hydrogen bonds and salt bridge anchors, indicating their potential in generating immune responses. Some of these identified epitopes can be potential candidates for the development of 2019-nCoV vaccines."],"journal":"J Med Virol","authors":["Baruah, Vargab","Bose, Sujoy"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32022276","source":"PubMed","week":"20206|Feb 03 - Feb 09","doi":"10.1002/jmv.25698","keywords":["2019-ncov","covid-19","sars-cov-2","coronavirus","epitope prediction","immunoinformatics"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490895597570,"score":313.40512},{"pmid":32483236,"title":"Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.","text":["Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.","Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.","Nat Commun","Poh, Chek Meng","Carissimo, Guillaume","Wang, Bei","Amrun, Siti Naqiah","Lee, Cheryl Yi-Pin","Chee, Rhonda Sin-Ling","Fong, Siew-Wai","Yeo, Nicholas Kim-Wah","Lee, Wen-Hsin","Torres-Ruesta, Anthony","Leo, Yee-Sin","Chen, Mark I-Cheng","Tan, Seow-Yen","Chai, Louis Yi Ann","Kalimuddin, Shirin","Kheng, Shirley Seah Gek","Thien, Siew-Yee","Young, Barnaby Edward","Lye, David C","Hanson, Brendon John","Wang, Cheng-I","Renia, Laurent","Ng, Lisa F P","32483236"],"abstract":["Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus."],"journal":"Nat Commun","authors":["Poh, Chek Meng","Carissimo, Guillaume","Wang, Bei","Amrun, Siti Naqiah","Lee, Cheryl Yi-Pin","Chee, Rhonda Sin-Ling","Fong, Siew-Wai","Yeo, Nicholas Kim-Wah","Lee, Wen-Hsin","Torres-Ruesta, Anthony","Leo, Yee-Sin","Chen, Mark I-Cheng","Tan, Seow-Yen","Chai, Louis Yi Ann","Kalimuddin, Shirin","Kheng, Shirley Seah Gek","Thien, Siew-Yee","Young, Barnaby Edward","Lye, David C","Hanson, Brendon John","Wang, Cheng-I","Renia, Laurent","Ng, Lisa F P"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32483236","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1038/s41467-020-16638-2","topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668704334372667393,"score":308.29712},{"pmid":32419646,"title":"Design of multi-epitope vaccine candidate against SARS-CoV-2: a In-Silico study.","text":["Design of multi-epitope vaccine candidate against SARS-CoV-2: a In-Silico study.","The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silica tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.","J Biomol Struct Dyn","K, Abraham Peele","T, Srihansa","S, Krupanidhi","A, Vijaya Sai","Tc, Venkateswarulu","32419646"],"abstract":["The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silica tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine candidate was designed using B and T-cell epitopes that can act as an immunogen and elicits immune response in the host system. NCBI was used for the retrieval of surface spike glycoprotein, of novel corona virus (SARS-CoV-2) strains. VaxiJen server screens the most important immunogen of all the proteins and IEDB server gives the prediction and analysis of B and T cell epitopes. Final vaccine construct was designed in silico composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19."],"journal":"J Biomol Struct Dyn","authors":["K, Abraham Peele","T, Srihansa","S, Krupanidhi","A, Vijaya Sai","Tc, Venkateswarulu"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419646","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/07391102.2020.1770127","keywords":["covid-19","iedb","spike glycoprotein","vaccine design","vaxigen","immuno-informatics"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284572487682,"score":305.65237},{"pmid":32372051,"title":"Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2.","text":["Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2.","To control and prevent the current COVID-19 pandemic, the development of novel vaccines is an emergent issue. In addition, we need to develop tools that can measure/monitor T-cell and B-cell responses to know how our immune system is responding to this deleterious virus. However, little information is currently available about the immune target epitopes of novel coronavirus (SARS-CoV-2) to induce host immune responses. Through a comprehensive bioinformatic screening of potential epitopes derived from the SARS-CoV-2 sequences for HLAs commonly present in the Japanese population, we identified 2013 and 1399 possible peptide epitopes that are likely to have the high affinity (<0.5%- and 2%-rank, respectively) to HLA class I and II molecules, respectively, that may induce CD8(+) and CD4(+) T-cell responses. These epitopes distributed across the structural (spike, envelope, membrane, and nucleocapsid proteins) and the nonstructural proteins (proteins corresponding to six open reading frames); however, we found several regions where high-affinity epitopes were significantly enriched. By comparing the sequences of these predicted T cell epitopes to the other coronaviruses, we identified 781 HLA-class I and 418 HLA-class II epitopes that have high homologies to SARS-CoV. To further select commonly-available epitopes that would be applicable to larger populations, we calculated population coverages based on the allele frequencies of HLA molecules, and found 2 HLA-class I epitopes covering 83.8% of the Japanese population. The findings in the current study provide us valuable information to design widely-available vaccine epitopes against SARS-CoV-2 and also provide the useful information for monitoring T-cell responses.","J Hum Genet","Kiyotani, Kazuma","Toyoshima, Yujiro","Nemoto, Kensaku","Nakamura, Yusuke","32372051"],"abstract":["To control and prevent the current COVID-19 pandemic, the development of novel vaccines is an emergent issue. In addition, we need to develop tools that can measure/monitor T-cell and B-cell responses to know how our immune system is responding to this deleterious virus. However, little information is currently available about the immune target epitopes of novel coronavirus (SARS-CoV-2) to induce host immune responses. Through a comprehensive bioinformatic screening of potential epitopes derived from the SARS-CoV-2 sequences for HLAs commonly present in the Japanese population, we identified 2013 and 1399 possible peptide epitopes that are likely to have the high affinity (<0.5%- and 2%-rank, respectively) to HLA class I and II molecules, respectively, that may induce CD8(+) and CD4(+) T-cell responses. These epitopes distributed across the structural (spike, envelope, membrane, and nucleocapsid proteins) and the nonstructural proteins (proteins corresponding to six open reading frames); however, we found several regions where high-affinity epitopes were significantly enriched. By comparing the sequences of these predicted T cell epitopes to the other coronaviruses, we identified 781 HLA-class I and 418 HLA-class II epitopes that have high homologies to SARS-CoV. To further select commonly-available epitopes that would be applicable to larger populations, we calculated population coverages based on the allele frequencies of HLA molecules, and found 2 HLA-class I epitopes covering 83.8% of the Japanese population. The findings in the current study provide us valuable information to design widely-available vaccine epitopes against SARS-CoV-2 and also provide the useful information for monitoring T-cell responses."],"journal":"J Hum Genet","authors":["Kiyotani, Kazuma","Toyoshima, Yujiro","Nemoto, Kensaku","Nakamura, Yusuke"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32372051","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s10038-020-0771-5","locations":["Japanese","Japanese"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138496429981697,"score":287.5973},{"pmid":32380200,"pmcid":"PMC7198429","title":"In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2.","text":["In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2.","An outbreak caused by 2019 novel coronavirus (2019-nCoV) was first identified in Wuhan City, Hubei Province, China. The new virus was later named SARS-CoV-2. The virus has affected tens of thousands of patients in the world. The infection of SARS-CoV-2 causes severe pneumonia and even death. It is urgently needed to find a therapeutic method to treat patients with SARS-CoV-2 infection. Studies showed that the surface spike (S) protein is essential for the coronavirus binding and entry of host cells. The heptad repeats 1 and 2 (HR1 and HR2) in the S protein play a decisive role in the fusion of the viral membrane with the host cell membrane. We predicted the HR1 and HR2 regions in S protein by sequence alignment. We simulated a computational model of HR1/2 regions and the fusion core. The binding energy of HR1 and HR2 of the fusion core was -33.4kCal/mol. We then designed antivirus peptides by molecular dynamics simulation of the fusion core. The binding energy of HR2-based antiviral peptide to HR1 was -43.0kCal/mol, which was stronger than the natural stage of the fusion core, suggesting that the predicted antiviral peptide can competitively bind with HR1 to prevent forming of the fusion core. The antiviral peptides can prevent SARS-CoV-2 membrane fusion and can potentially be used for the prevention and treatment of infections.","Peptides","Ling, Rongsong","Dai, Yarong","Huang, Boxuan","Huang, Wenjie","Lu, Xifeng","Jiang, Yizhou","32380200"],"abstract":["An outbreak caused by 2019 novel coronavirus (2019-nCoV) was first identified in Wuhan City, Hubei Province, China. The new virus was later named SARS-CoV-2. The virus has affected tens of thousands of patients in the world. The infection of SARS-CoV-2 causes severe pneumonia and even death. It is urgently needed to find a therapeutic method to treat patients with SARS-CoV-2 infection. Studies showed that the surface spike (S) protein is essential for the coronavirus binding and entry of host cells. The heptad repeats 1 and 2 (HR1 and HR2) in the S protein play a decisive role in the fusion of the viral membrane with the host cell membrane. We predicted the HR1 and HR2 regions in S protein by sequence alignment. We simulated a computational model of HR1/2 regions and the fusion core. The binding energy of HR1 and HR2 of the fusion core was -33.4kCal/mol. We then designed antivirus peptides by molecular dynamics simulation of the fusion core. The binding energy of HR2-based antiviral peptide to HR1 was -43.0kCal/mol, which was stronger than the natural stage of the fusion core, suggesting that the predicted antiviral peptide can competitively bind with HR1 to prevent forming of the fusion core. The antiviral peptides can prevent SARS-CoV-2 membrane fusion and can potentially be used for the prevention and treatment of infections."],"journal":"Peptides","authors":["Ling, Rongsong","Dai, Yarong","Huang, Boxuan","Huang, Wenjie","Lu, Xifeng","Jiang, Yizhou"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380200","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.peptides.2020.170328","keywords":["blocking peptide","molecular dynamics","sars-cov-2","spike protein"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097364783104,"score":282.2001}]}